A Phase I/II Study of Nivolumab plus or minus Ipilimumab in Combination with Multi-fraction Stereotactic Radiosurgery for Recurrent High-grade Radiation-relapsed Meningioma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients must have histologically confirmed WHO grade II-III meningioma which has relapsed after prior radiation therapy with radiologically progressive or recurrent disease. 2) Patients must have measurable disease, defined as at least 1 lesion that can be accurately measured in at least one dimension as =1 cm on brain MRI but with the maximum dimension = 5 cm OR gross tumor volume < 20 cm3. 3) Patients must have at least one prior surgery with available archival formalin-fixed paraffin-embedded (FFPE) tumor blocks of the initial or recurrent meningioma.

You may not be eligible for this study if the following are true:

  • 1) Patients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. 2) Patients who have had radiation therapy (to the site of reirradiation) within 6 months prior to entering the study. 3) Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1); however, alopecia, sensory neuropathy = grade 2, or other = grade 2 not constituting a safety risk based on the investigator’s judgmentare acceptable.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.